Myra W. Popejoy

发表

Reply to Chao and Lai

R. Wunderink, S. Fujimi, J. Butterton, 2022, Clinical Infectious Diseases.

Analysis of patients with diabetes and complicated intra-abdominal infection or complicated urinary tract infection in phase 3 trials of ceftolozane/tazobactam

J. Long, Myra W. Popejoy, Jennifer A. Huntington, 2017, BMC Infectious Diseases.

Efficacy of ceftolozane/tazobactam against urinary tract and intra-abdominal infections caused by ESBL-producing Escherichia coli and Klebsiella pneumoniae: a pooled analysis of Phase 3 clinical trials

D. Paterson, K. Kaye, E. Hershberger, 2017, The Journal of antimicrobial chemotherapy.

Characteristics and Outcomes of Complicated Intra-abdominal Infections Involving Pseudomonas aeruginosa from a Randomized, Double-Blind, Phase 3 Ceftolozane-Tazobactam Study

J. Alverdy, E. Hershberger, J. Steenbergen, 2016, Antimicrobial Agents and Chemotherapy.

Does moderate renal impairment affect clinical outcomes in complicated intra-abdominal and complicated urinary tract infections? Analysis of two randomized controlled trials with ceftolozane/tazobactam

R. Kullar, J. Long, F. Wagenlehner, 2016, The Journal of antimicrobial chemotherapy.

Ceftolozane/Tazobactam Plus Metronidazole for Complicated Intra-abdominal Infections in an Era of Multidrug Resistance: Results From a Randomized, Double-Blind, Phase 3 Trial (ASPECT-cIAI)

P. Barie, J. Solomkin, C. Eckmann, 2015, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

PK/PD Target Attainment With Ceftolozane/Tazobactam Using Monte Carlo Simulation in Patients With Various Degrees of Renal Function, Including Augmented Renal Clearance and End-Stage Renal Disease

R. Kullar, A. Xiao, L. Caro, 2016, Infectious Diseases and Therapy.

A Phase 3, Randomized, Double-Blind Study Comparing Tedizolid Phosphate and Linezolid for Treatment of Ventilated Gram-Positive Hospital-Acquired or Ventilator-Associated Bacterial Pneumonia

R. Wunderink, S. Fujimi, J. Butterton, 2021, Clinical Infectious Diseases.

Randomized Multicenter Study Comparing Safety and Efficacy of Daptomycin Versus Standard-of-care in Pediatric Patients With Staphylococcal Bacteremia

P. Bokesch, J. Bradley, N. Kartsonis, 2018, The Pediatric infectious disease journal.

Safety and Efficacy of Ceftolozane/Tazobactam Plus Metronidazole Versus Meropenem From a Phase 2, Randomized Clinical Trial in Pediatric Participants With Complicated Intra-abdominal Infection

Elizabeth G. Rhee, J. Newland, Julia D. Lonchar, 2023, The Pediatric infectious disease journal.

Safety and Efficacy of Ceftolozane/Tazobactam Versus Meropenem in Neonates and Children With Complicated Urinary Tract Infection, Including Pyelonephritis: A Phase 2, Randomized Clinical Trial

Elizabeth G. Rhee, E. Roilides, J. Bradley, 2023, The Pediatric infectious disease journal.

Efficacy and Safety of Adintrevimab (ADG20) for the Treatment of High-Risk Ambulatory Patients With Mild or Moderate Coronavirus Disease 2019: Results From a Phase 2/3, Randomized, Placebo-Controlled Trial (STAMP) Conducted During Delta Predominance and Early Emergence of Omicron

M. Dimopoulos, N. Nikolaev, M. Ison, 2023, Open forum infectious diseases.

591. Adintrevimab (ADI) Population Pharmacokinetics (PPK) in Phase 1 and Phase 2/3 COVID-19 Prevention and Treatment Study Participants

P. Ambrose, C. Rubino, Myra W. Popejoy, 2022, Open Forum Infectious Diseases.

Daptomycin for Pediatric Gram-Positive Acute Hematogenous Osteomyelitis

P. Bokesch, J. Bradley, M. Dorr, 2020, The Pediatric infectious disease journal.

1154. Safety and Efficacy of Ceftolozane/Tazobactam Plus Metronidazole Versus Meropenem in Pediatric Participants With Complicated Intra-abdominal Infection: A Phase 2, Randomized Clinical Trial

Elizabeth G. Rhee, J. Newland, Julia D. Lonchar, 2021, Open Forum Infectious Diseases.

Reply to Author.

R. Wunderink, S. Fujimi, J. Butterton, 2021, Clinical Infectious Diseases.